MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2024

“Our study shows a superior profile with the combination of fostrox and Lenvima in advanced liver cancer”     April – June Financial summary for the quarter · Net turnover amounted to SEK 1.1 (2.0) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -36.7 (-26.3) million. Basic and diluted earnings per share amounted to SEK -0.32 (-0.47). · Cash flow from operating activities amounted to SEK -26.3 (-17.9) million. · Cash and cash equivalents at the end of the period amounted to SEK 126.7 (82.8) million.